Gilder Gagnon Howe & Co. LLC Has $203.69 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

Gilder Gagnon Howe & Co. LLC trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 7.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,286,728 shares of the medical research company's stock after selling 103,743 shares during the period. Natera comprises about 2.2% of Gilder Gagnon Howe & Co. LLC's portfolio, making the stock its 10th biggest position. Gilder Gagnon Howe & Co. LLC owned 0.97% of Natera worth $203,689,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in NTRA. Kovitz Investment Group Partners LLC purchased a new stake in shares of Natera in the 4th quarter valued at approximately $211,000. Science & Technology Partners L.P. acquired a new stake in Natera in the fourth quarter valued at $25,490,000. Integrated Wealth Concepts LLC purchased a new stake in Natera during the 4th quarter worth about $232,000. RiverPark Advisors LLC boosted its holdings in Natera by 12.5% in the fourth quarter. RiverPark Advisors LLC now owns 3,767 shares of the medical research company's stock valued at $596,000 after purchasing an additional 420 shares in the last quarter. Finally, Syon Capital LLC acquired a new stake in shares of Natera during the fourth quarter worth about $403,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on NTRA. Robert W. Baird upped their target price on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Morgan Stanley boosted their target price on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Canaccord Genuity Group reissued a "buy" rating and issued a $180.00 price target on shares of Natera in a report on Wednesday, February 26th. Piper Sandler upped their price objective on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Finally, Royal Bank of Canada initiated coverage on Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price for the company. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $175.76.

Natera Price Performance

Shares of NASDAQ NTRA traded up $1.31 during mid-day trading on Thursday, reaching $152.24. 371,734 shares of the company traded hands, compared to its average volume of 1,377,018. Natera, Inc. has a fifty-two week low of $92.01 and a fifty-two week high of $183.00. The firm has a market cap of $20.58 billion, a PE ratio of -86.46 and a beta of 1.80. The stock has a fifty day simple moving average of $147.06 and a 200-day simple moving average of $153.86. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Activity

In other Natera news, insider John Fesko sold 663 shares of the company's stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the transaction, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Burkes Brophy sold 1,886 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $176.60, for a total value of $333,067.60. Following the sale, the chief financial officer now owns 101,811 shares of the company's stock, valued at approximately $17,979,822.60. This represents a 1.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 184,507 shares of company stock valued at $28,060,144 over the last three months. Insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.